Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

BioVectra ramps up cannabidiol in Canada

by Rick Mullin
March 29, 2019 | A version of this story appeared in Volume 97, Issue 13

 

The structure of cannabidiol.

The drug-service firm BioVectra will produce fully synthetic cannabidiol as an ­active pharmaceutical ingredient at its plant in Charlottetown, Prince Edward Island. The firm says its work with cannabinoids dates back to the early 2000s when it developed a supply of tetrahydrocannabinol. Meanwhile, BioVectra has launched a $1.5 million project to replace large-scale synthetic reactors and upgrade analytical services in Charlottetown.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.